Business
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
Summit Therapeutics plc(‘Summit' or the ‘Company')Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in
About this update from Summit Therapeutics Inc.
[{"type":"text","content":"Summit Therapeutics plc(‘Summit' or the ‘Company')Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019DDS-04 Series Cures Enterobacteriaceae Infection in Animal Model Potential in Lung, Bloodstream and Urinary Tract InfectionsActivity Shown Against Resistant and Non-Resistant StrainsEnterobacteriaceae are Gram-Negative Bacteria that Cause a Large Number of Serious InfectionsOxford, UK, and Cambridge, MA, US, 14 April 2019 - Summit Therapeutics plc (NASDAQ: SMMT, AIM:SUMM), a leader in new mechanism antibiotic innovation, today presented in vivo proof of concept data for the DDS-04 series of new mechanism antibiotics targeting Enterobacteriaceae in an oral session at the 29thEuropean Congress of Clinical Microbiology & Infectious Diseases (‘ECCMID') in Amsterdam.Enterobacteriaceae are a family of Gram-negative bacteria responsible for a large number of severe and often deadly infections. In the data presented, a DDS-04 series compound cured infection in a translationally-relevant animal model of urinary tract infection, one of the major sites for Enterobacteriaceae infection. Therapeutic concentrations of the DDS-04 compound were also observed in other major sites in the animal model where life-threatening Enterobacteriaceae infections occur, including the lungs and the bloodstream.\"Patients with Enterobacteriaceae infections are increasingly at risk for poor outcomes due to the spread of antimicrobial resistance,\"saidDr David Roblin, President of R&D of Summit. \"Mainstay treatments are losing their effectiveness, and patients do not have the luxury of time to fail antibiotic therapy. There is a pressing need for new, targeted Enterobacteriaceae antibiotics that can serve to improve patient outcomes.\"The DDS-04 series acts via LolCDE, a novel bacterial target. The LolCDE site of DDS-04 series activity is conserved in the majority of therapeutically important Enterobacteriaceae, resulting in targeted spectrum compounds. With its new mechanism of action, the DDS-04 series was rapidly bactericidal and highly potent across globally diverse Enterobacteriaceae strains in research studies, which included multi-drug resistant isolates. Importantly, the DDS-04 series also showed low propensity for resistance development and did not show cross-resistance...